Sleep duration and napping in relation to colorectal and gastric cancer in the MCC-Spain study

Kyriaki Papantoniou1,2, Gemma Castaño-Vinyals3,4,5, Ana Espinosa2,3,4,5, Michelle C. Turner2,3,4,6, Vicente Martín-Sánchez6,7, Delphine Casabonne4,8, Nuria Aragonés4,9, Inés Gómez-Acebo6,10,11, Eva Ardanaz4,12,13, Jose-Juan Jimenez-Moleon4,14,15, Pilar Amiano4,16,17, Ana Molina-Barceló18, Juan Alguacil16,19, Guillermo Fernández-Tardón4,20, José María Huerta8,21, Natalia Hernández-Segura7, Beatriz Perez-Gomez4,22,23, Javier Llorca4,10, Juana Vidán-Alli4,12,13, Rocío Olmedo-Requena4,14,15, Leire Gil4,16,17, Carmen Castañon-López24, Marina Pollan4,22, Manolis Kogevinas2,3,4,5 & Victor Moreno4,25,26,27

Sleep duration is a novel and potentially modifiable risk factor for cancer. We evaluated the association of self-reported sleep duration and daytime napping with odds of colorectal and gastric cancer. We included 2008 incident colorectal cancer cases, 542 gastric cancer cases and 3622 frequency-matched population controls, recruited in the MCC-Spain case-control study (2008–2013). Sleep information, socio-demographic and lifestyle characteristics were obtained through personal interviews. Multivariable adjusted logistic regression models were used to estimate odds ratios (OR) with 95% confidence intervals (CI) for cancer, across categories of sleep duration (≤ 5, 6, 7, 8, ≥ 9 hours/day), daytime napping frequency (naps/week) and duration (minutes/nap). Compared to 7 hours of sleep, long sleep was associated with increased odds of colorectal (OR≥9 hours: 1.59; 95%CI 1.30–1.94) and gastric cancer (OR≥9 hours: 1.95; 1.37–2.76); short sleep was associated with increased odds of gastric cancer (OR≤5 hours: 1.32; 0.93–1.88). Frequent and long daytime naps increased the odds of colorectal (OR6–7 naps/week, ≥30 min: 1.32; 1.14–1.54) and gastric cancer (OR6–7 naps/week, ≥30 min: 1.56; 1.21–2.02). Effects of short sleep and frequent long naps were stronger among participants with night shift-work history. Sleep and circadian disruption may jointly play a role in the etiology of colorectal and gastric cancer.

1Department of Epidemiology, Center of Public Health, Medical University of Vienna, Kindеспitalgasse 15, 1090 Vienna, Austria. 2ISGlobal, Barcelona, Spain. 3Universitat Pompeu Fabra (UPF), Barcelona, Spain. 4Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain. 5IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain. 6McLaughlin Centre for Population Health Risk Assessment, University of Ottawa, Ottawa, ON, Canada. 7Biomedicine Institute (IBIOMED), University of León, Leon, Spain. 8Unit of Molecular and Genetic Epidemiology in Infections and Cancer (UNIC-Molecular), Cancer Epidemiology Research Programme, IDIBELL, Catalan Institute of Oncology, Hospital de Lloret, Barcelona, Spain. 9Epidemiology Section, Public Health Division, Department of Health of Madrid, Madrid, Spain. 10University of Cantabria, Santander, Spain. 11IDIVAL, Santander, Spain. 12Navarra Public Health Institute, Pamplona, Spain. 13idISNA, Navarra Institute for Health Research, Pamplona, Spain. 14Department of Preventive Medicine and Public Health, University of Granada, Granada, Spain. 15Instituto de Investigación Biosanitaria de Granada(lbs.GRANADA), Hospitales Universitarios de Granada/Universidad de Granada, Granada, Spain. 16Public Health Division of Gipuzkoa, San Sebastian, Spain. 17Biodonostia Research Institute, San Sebastian, Spain. 18Cancer and Public Health Area, FISABIO-Public Health, Valencia, Spain. 19Centro de Investigación en Salud y Medio Ambiente (CYSMA), Universidad de Huelva, Campus Universitario de El Carmen, Huelva, Spain. 20Health Research Institute of the Principality of Asturias, University of Oviedo, Oviedo, Spain. 21Department of Epidemiology, Murcia Regional Health Council, IMIB-Arrixaca, Murcia, Spain. 22Cancer Epidemiology Unit of the National Center for Epidemiology, Carlos III Institute of Health, Madrid, Spain. 23Cancer Epidemiology Research Group, Oncology and Hematology Area, IIS Puerta de Hierro (IDIPHIM), Majadahonda, Madrid, Spain. 24Servicio de Oncología, Complejo Asistencial Universitario de León, Leon, Spain. 25Unit of Biomarkers and Susceptibility, Oncology Data Analytics Program, Catalan Institute of Oncology (ICO), Hospital de Lloret, Barcelona, Spain. 26Colorectal Cancer Group, ONCOBELL Program, Bellvitge Biomedical Research Institute (IDIBELL), Hospital de Lloret, Barcelona, Spain. 27Department of Clinical Sciences, Faculty of Medicine, University of Barcelona, Barcelona, Spain. 28email: kyriaki.papantoniou@meduniwien.ac.at
Colorectal cancer (CRC) is the third most common cancer worldwide (1,800,977 new cases in 2018), and the second most common cause of cancer death (861,663 deaths in 2018). Gastric cancer is the sixth most commonly diagnosed cancer (1,033,701 new cases) and third cause of cancer death (782,685 deaths). CRC incidence rates overall have declined since the mid-1980s because of changing patterns in risk factors and screening. However, CRC occurrence has been on the rise in patients younger than age 50 for unknown reasons. Despite extensive research on the etiology and advancements in early detection and treatment of colorectal and gastric tumors, more research on identifying modifiable risk factors is needed.

Sleep duration has been suggested as a novel and potentially modifiable risk factor for chronic disease incidence and mortality. Specifically, short and long sleep duration have been associated with a higher risk for cardiovascular disease, type II diabetes, obesity, and cancer. Most studies of cancer so far have focused on the effects of sleep duration on breast cancer and the evidence on other tumors is limited. Long sleep duration has been associated with an increased risk of colorectal cancer in two prospective cohorts of health professionals, especially among individuals who were overweight or snored regularly. Long and short sleep were both associated with an elevated risk of CRC in a cohort study of postmenopausal women. So far only one study, a prospective cohort of older adults, has reported an increased risk for gastric cancer associated with short sleep. In a recent study prediagnosis short sleep and long napping were associated with significantly higher mortality among CRC survivors. No previous study has, to our knowledge, evaluated daytime napping as a risk factor for colorectal and gastric cancer.

Our aim in the present study was to evaluate habitual sleep duration and daytime napping in relation to colorectal and gastric cancer adjusting for potential confounders and other sleep characteristics in a large population based case–control study. Long-term night shift work has been shown to increase the odds of colorectal and gastric cancer in our previous analyses. Therefore, we additionally conducted stratified analyses by night shift work history to evaluate potential joint effects of sleep and circadian disruption in relation to gastrointestinal cancer risk.

Methods
The MCC-Spain Study is a population-based case–control study on five tumors (breast, colorectal, prostate, stomach and chronic lymphocytic leukemia) in Spain, with the general aim to investigate environmental and genetic factors related to cancer risk. Methods used in this study have been previously reported in detail. In brief, the study recruited incident cancer cases from 23 hospitals in 12 different regions in Spain and a common set of population controls for all cases. The recruitment of cancer cases and controls study began in the year 2008 and was conducted through 2013. All procedures performed in studies involving human participants were in accordance with the ethical standards of the research committee, and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The protocol of MCC-Spain was approved by each of the ethics committees of the participating institutions (Ethical Committee of Clinical Research of Barcelona, Cantabria, Girona, Gipuzkoa, Huelva, León, Principado de Asturias, Madrid, Navarra and Valencia). All participants provided informed consent prior to enrolment into the study. The study underlying this article cannot be shared publicly for the privacy of individuals that participated in the study. The data can be shared on reasonable request to the corresponding author and coordinator of the study.

Study population. Cases were males and females, aged 20–85 years with a new histological confirmed diagnosis of colorectal or gastric cancer living in the catchment area of each hospital for at least 6 months. Cases were defined by the International Classification of Disease 10 (ICD-10) codes: C18, C19, C20, D01.0, D01.1, D01.2 for colon or rectum, C16 and D00.2 for stomach and C15.5 for cancer cases of the lower third of the oesophagus. Clinical data such as CRC histological type (adenocarcinoma, mucinous adenocarcinoma, signet ring-cell carcinoma, squamous cell carcinoma, medullary carcinoma, undifferentiated carcinoma, other, type not specified), tumor localization (proximal colon, distal colon, rectum), and TNM staging information was available through hospital medical records. Most CRC tumors were adenocarcinomas (92% adenocarcinomas, 5.5% mucinous carcinomas, 1.5% other types, 1% not specified). Most colorectal cancers (52%) were at clinical stage II or lower at recruitment, and in 110 patients (5.3%) we could not establish the clinical stage. Clinical data for gastric cancer included tumor histological type, localization, Lauren classification, the 2010 classification of the WHO and degree of differentiation. Data on Helicobacter pylori (H. pylori) status were available in 279 cases, with 93% positive. Controls living in the same catchment area as cases for the same period of time (≥ 6 months) were randomly selected from the rosters of General Practitioners (GP) at the Primary Health Centers (PHC) included in the study. They were contacted on behalf of their GP and invited to participate in the study. Controls were frequency-matched to the overall distribution of cases, by age, sex and center, ensuring that in each center there was at least one control of the same sex and 5-year interval for each case. Eligible controls were free of CRC or gastric cancer history, respectively. Subjects were ineligible if they were incapable to participate in the interview due to communication difficulties (e.g. speaking problems) or excess impairment of physical ability. Response rates among cases and controls varied by center and on average were 68% among colorectal cancer cases, 55% among gastric cancer cases and 54% among controls with valid telephone numbers. There were no differences in educational level and age between those subjects who participated and those who did not respond to the study invitation or refused to participate. A total of 2140 CRC cases, 459 gastric cancer cases, 3950 controls for colorectal cancer and 3440 controls for gastric cancer were recruited in the study. Participants with missing information on sleep duration (N = 487, 7.3%) and key confounders (N = 7, 0.1%) were excluded. The present analysis included 2008 colorectal cancer cases, 452 gastric cancer cases, 3598 controls for colorectal cancer and 3099 population controls for gastric cancer (3077 were common controls used in both analyses).
Data collection. Participant information was collected using face-to-face interviews performed by trained personnel. Interviews with cancer patients were scheduled shortly after a new cancer diagnosis. The median time between date of diagnosis and interview was 63 days (interquartile range, iqr 106) for colorectal cancer and 40 days (iqr 75) for gastric cancer. To evaluate sleep duration, subjects were asked to report how many hours on average they slept per night at the time of recruitment. They were also asked how frequently (days/week) they usually took daytime naps (“siestas”) and what was their average duration (minutes/nap). Sleep quality was assessed using questions on occurrence of sleep problems (difficulty falling asleep, waking up during the night, taking sleep medication) that lasted for at least 1 year through lifetime and also by reporting the the age of beginning and end of the sleep problem. Sleep timing was assessed asking participants to report their habitual bedtime, if they reported going to sleep at approximately the same time every day during the last 10 years, and whether they had experienced a period of at least 1 year with frequent changes in their bedtime. Night shift work (working for at least 3 h between midnight and 5am at least 3 times per month) was assessed using a lifetime occupational history and detailed questions on work schedules for all jobs held for at least a year. Information on known or suspected risk factors for colorectal and gastric cancer was collected including age, educational level, family socioeconomic level, race, BMI, family history of colorectal and gastric cancer, smoking status, physical activity, medication use, and personal disease history (e.g. diabetes). In a subset of participants (88% of controls, 88% of colorectal cancer cases, 77% of gastric cancer cases) a self-administered diet questionnaire was used to assess current and past (at the age of 30–40 years) diet habits including alcohol consumption.

Statistical analysis. In bivariate analyses we examined participant’s characteristics by case–control status and by categories of sleep duration and daytime napping. We used generalized additive models (GAM) to inspect the linearity of associations of sleep duration with CRC and gastric cancer. GAMs used a smoothing function for sleep duration and were adjusted for confounders. We used unconditional logistic regression analysis and calculated odds ratios (OR) with 95% confidence intervals (CI) for colorectal and gastric cancer separately, across predefined categories of: (i) nighttime sleep duration (≤ 5 hours, 6 hours, 7 hours (reference), 8 hours, ≥ 9 hours), (ii) daytime napping frequency (no napping (reference), 1–5 days/week, 6–7 days/week), (iii) daytime napping duration (no napping, < 15 min, 15–29 min, 30–59 min, ≥ 60 min), (iv) combined napping frequency and duration (no napping, 1–5 naps/week for < 30 min, 6–7 naps/week for < 30 min, 1–5 naps/week for ≥ 30 min, 6–7 naps/week for ≥ 30 min). For the combined analysis, the median of napping duration (30 min) and the 25th percentile of napping frequency (5 days/week) among controls that napped were used as cut-offs. We also assessed the effects of ever having sleep problems (for at least 1 year), duration of sleep problems (years) and having experienced frequent changes in bedtime. Crude models were adjusted for frequency-matched variables (age, center, sex) and educational level (less than primary, primary, high school, university). Fully-adjusted models were additionally adjusted for family history of CRC or gastric cancer in first degree relatives (yes/no), body mass index (< 25, 25–29, ≥ 30 units), leisure time physical activity (inactive, little active, moderately active, very active)), smoking status (never, ex-smoker, current smoker) and occupational status (employed, unemployed, housewives, retired). A category of missing values was used for confounders included in the final model. Full case-analysis was performed in a subset of participants (88% of controls, 88% of colorectal cancer cases, 77% of gastric cancer cases) with diet information on usual and past dietary intake. In this analysis we additionally adjusted for diet habits [past alcohol consumption (quartiles), total energy intake in grams/day (quartiles), red meat consumption in grams/day (quartiles), fruit consumption in grams/day (quartiles), vegetable consumption in grams/day (quartiles)], other sleep characteristics (sleep duration/daytime napping, sleep problems, frequent changes in bedtime), and night shift work history (never shift work, permanent night shifts, rotating night shifts, rotating shifts, housewives). Further adjustment to the above mentioned variables made minimal difference in risk estimates and these results are presented in Supplemental Table 1. We tested possible interactions between sleep duration/daytime napping and sex (women, men), BMI (< 25, 25–30, > 30), night shift work history (never, ever), education (primary school or less vs high school, university or higher) and age at recruitment/diagnosis (< 50 years, ≥ 50 years) using the likelihood ratio test (LRT) and performed stratified analyses. Stratified analysis by night shift work history (never, ever) was conducted among participants with night shift work information (87.5%), after excluding participants with missing night shift work history (CRC: 7.9%, gastric: 5.8%) and housewives (CRC/gastric: 6.7%). We also evaluated the association between sleep duration and daytime napping and anatomical subtypes (colon, rectum), and TNM staging (0–II, III, IV) of colorectal cancer and anatomical site (non-cardia/esophageal, cardia) and Lauren classification (Intestinal vs Diffuse) for gastric cancer using multivariate logistic regression model for heterogeneity across subtypes of cancer. In sensitivity analysis we (i) excluded participants with any report of sleep problem in the 5 years prior to recruitment in the study (N = 1930, 31.7% (ii) excluded retired workers (N = 3146, 52%), (iii) excluded participants with more than 6 months between the date of diagnosis and interview. Analyses were performed using Stata version 14.1.

Compliance with ethical standards. Ethical approval was obtained from the local ethical committee. Informed consent was obtained from all participants. All methods were carried out in accordance with relevant guidelines and regulations.

Results
CRC cases were more likely to be older, obese, less physically active, to smoke, to have a lower educational level and to report CRC in their family history, than controls (Table 1). Similarly, gastric cancer cases were older and more likely to be obese, physically inactive, ever smokers, and to have family history of gastric cancer, compared to controls. Both colorectal and gastric cancer cases reported higher total energy intake, past alcohol consumption and red meat consumption compared to their respective controls. Average sleep duration was slightly longer

Scientific Reports | (2021) 11:21822 | https://doi.org/10.1038/s41598-021-91275-3

natureportfolio
among cases (CRC 7.3 h; SD1.6; gastric cancer 7.2 h; SD 1.6) than controls (7 h; SD 1.4). Daytime napping was reported among 61% of colorectal cancer cases, 60% of gastric cancer cases and approximately 55% of population controls. Both colorectal and gastric cancer cases were more likely to report a higher frequency (days/week) and duration (minutes/nap) of daytime napping compared to controls. Sleep problems and use of sleep medication was more frequent among controls than among cancer cases.

Controls in the extreme sleep duration categories (≤ 5 and ≥ 9 h) were more likely to be older and retired, have a higher BMI, lower education, and be less physically active, compared to those with 7 h of sleep (Table 2). Controls with the longest durations of sleep (≥ 9 h) were also more likely to be male, to have night shift work history and report higher past alcohol consumption, compared to participants with shorter sleep duration. Controls who slept ≤ 5 h were more likely to have sleep problems, take sleep medication, and report frequent changes in bed time. Daytime napping was less common in the extreme sleep duration categories, compared to the 7 h group, however frequency and duration of naps was higher in participants with extreme nighttime sleep duration, compared to 7 h of sleep. Participants napping 6–7 times a week were slightly older and more likely to be male, retired workers, smokers and less likely to have sleep problems. Sleep duration was similar between participants with and without napping and across categories of increasing napping frequency.

We found a U-shape association between sleep duration and gastric cancer as shown in the multivariable adjusted GAM spline (Fig. 1). A similar but less pronounced shape of association was observed for CRC. The quadratic term of sleep duration was statistically significant (p < 0.001) for both colorectal and gastric cancer risk, showing departure from linearity. Associations of sleep duration categories, daytime naps with incident colorectal and gastric cancer are presented in Table 3. In multivariable adjusted models sleep duration of 8 h and ≥ 9 h were associated with an increase in the odds of CRC (OR_8 hours: 1.27; 95% CI 1.08–1.49, OR_9 hours: 1.59; 1.30–1.94) and gastric cancer (OR_8 hours: 1.46; 95% CI 1.09–1.97, OR_9 hours: 1.95; 1.35–2.76), compared to

| Characteristics | Controls for colorectal cancer (N = 3598)* | Colorectal cancer cases (N = 2008) | Controls for gastric cancer (N = 3099)* | Gastric cancer cases (N = 452) |
|-----------------|------------------------------------------|----------------------------------|----------------------------------------|-------------------------------|
| Age; mean (SD)  | 63.2 (11.8)                              | 66.9 (10.8)                      | 64.0 (11.5)                            | 66.4 (12.4)                   |
| BMI (kg/m²); mean (SD) | 26.7 (4.5)                              | 27.5 (4.5)                      | 26.9 (4.4)                            | 27.6 (4.2)                   |
| Women (%)       | 49.4                                     | 36.3                            | 45.2                                   | 33.0                         |
| Postmenopausal (%) | 72.7                                     | 90.0                            | 75.1                                   | 88.6                         |
| Obese (%)       | 21.1                                     | 25.5                            | 21.5                                   | 25.7                         |
| Primary school or less (%) | 52.3                                     | 69.1                            | 54.0                                   | 68.8                         |
| Never smokers (%) | 44.5                                     | 41.3                            | 44.2                                   | 40.7                         |
| Physically inactive (METs hour/week) (%) | 40.7                                     | 48.9                            | 42.0                                   | 50.7                         |
| Family history of colorectal cancer (%) | 8.2                                     | 16.6                            | 8.6                                    | 10.6                         |
| Family history of gastric cancer (%) | 6.0                                     | 6.5                             | 6.1                                    | 15.5                         |
| Night shift work history (%) | 16.8                                     | 16.9                            | 17.1                                   | 19.5                         |
| Retired (%)     | 48.0                                     | 58.1                            | 51.6                                   | 53.5                         |
| Diet habits; mean (SD)* |                                |                                  |                                        |                               |
| Total energy intake (kcal/day) | 1896 (637)                             | 2010 (704)                      | 1907 (640)                            | 2183 (858)                   |
| Past alcohol consumption (g ethanol/day) | 17.3 (27.0)                             | 24.3 (34.1)                     | 18.1 (27.5)                           | 27.8 (24.2)                  |
| All red meat consumption (g/day) | 61.8 (38.8)                             | 74.0 (48.7)                     | 62.9 (38.8)                           | 84.6 (54.8)                  |
| Fruit consumption (g/day) | 349 (217)                               | 345 (204)                       | 353 (218)                            | 356 (234)                    |
| Vegetable consumption (g/day) | 190 (123)                               | 172 (109)                       | 192 (126)                            | 181 (126)                    |

Table 1. Characteristics of controls and cases with sleep duration information in the MCC-Spain study (N = 6082). Some column totals do not add up due to missing data. BMI body mass index, METs metabolic equivalents, SD standard deviation. *3077 of the controls are common controls for colorectal and gastric cancer. Study subset (3193 colorectal cancer controls, 1773 colorectal cancer cases, 349 gastric cancer cases and 2732 gastric cancer controls). Computed among participants who reported daytime napping.

among cases (CRC 7.3 h; SD1.6; gastric cancer 7.2 h; SD 1.6) than controls (7 h; SD 1.4). Daytime napping was reported among 61% of colorectal cancer cases, 60% of gastric cancer cases and approximately 55% of population controls. Both colorectal and gastric cancer cases were more likely to report a higher frequency (days/week) and duration (minutes/nap) of daytime napping compared to controls. Sleep problems and use of sleep medication was more frequent among controls than among cancer cases.

Controls in the extreme sleep duration categories (≤ 5 and ≥ 9 h) were more likely to be older and retired, have a higher BMI, lower education, and be less physically active, compared to those with 7 h of sleep (Table 2). Controls with the longest durations of sleep (≥ 9 h) were also more likely to be male, to have night shift work history and report higher past alcohol consumption, compared to participants with shorter sleep duration. Controls who slept ≤ 5 h were more likely to have sleep problems, take sleep medication, and report frequent changes in bed time. Daytime napping was less common in the extreme sleep duration categories, compared to the 7 h group, however frequency and duration of naps was higher in participants with extreme nighttime sleep duration, compared to 7 h of sleep. Participants napping 6–7 times a week were slightly older and more likely to be male, retired workers, smokers and less likely to have sleep problems. Sleep duration was similar between participants with and without napping and across categories of increasing napping frequency.

We found a U-shape association between sleep duration and gastric cancer as shown in the multivariable adjusted GAM spline (Fig. 1). A similar but less pronounced shape of association was observed for CRC. The quadratic term of sleep duration was statistically significant (p < 0.001) for both colorectal and gastric cancer risk, showing departure from linearity. Associations of sleep duration categories, daytime naps with incident colorectal and gastric cancer are presented in Table 3. In multivariable adjusted models sleep duration of 8 h and ≥ 9 h were associated with an increase in the odds of CRC (OR_8 hours: 1.27; 95% CI 1.08–1.49, OR_9 hours: 1.59; 1.30–1.94) and gastric cancer (OR_8 hours: 1.46; 95% CI 1.09–1.97, OR_9 hours: 1.95; 1.35–2.76), compared to
Table 2. Characteristics of sleep duration and daytime napping profiles among all controls included in the analysis of colorectal cancer (N = 3598). *Computed among participants with reported daytime napping. BMI body mass index, METS metabolic equivalents, SD standard deviation, iqr interquartile range.

| Characteristics | Sleep duration (hours/day) (N = 3598) | Daytime napping frequency (N=3496) |
|----------------|---------------------------------------|-------------------------------------|
|                | ≤5 | 6 | 7 | 8 | ≥9 | No naps | Napping 1–5 days/week | Napping 6–7 days/week |
| N              | 472 | 724 | 1048 | 987 | 368 | 1534 | 555 | 1407 |
| Age; mean (SD) | 65.1 (10.7) | 62.5 (11.4) | 60.4 (11.9) | 63.7 (11.9) | 68.8 (10.4) | 62.1 (12.3) | 58.4 | 66.4 (10.0) |
| BMI; mean (SD) | 27.3 (4.7) | 27.2 (4.6) | 26.2 (4.2) | 26.5 (4.3) | 27.4 (4.8) | 26.6 (4.6) | 26.1 (4.2) | 27.2 (4.3) |
| Women (%)      | 51.1 | 49.5 | 50.9 | 49.2 | 42.9 | 59.1 | 50.8 | 36.5 |
| Obese (%)      | 23.9 | 23.8 | 16.8 | 19.6 | 28.5 | 20.6 | 16.8 | 23.6 |
| Primary school or less (%) | 63.5 | 51.7 | 41.8 | 49.4 | 74.2 | 54.4 | 38.0 | 56.0 |
| Never smoker (%) | 49.8 | 39.6 | 42.8 | 44.6 | 51.9 | 50.3 | 38.6 | 40.4 |
| Physically Inactive (METS hour/week) (%) | 44.5 | 43.1 | 36.5 | 39.6 | 45.9 | 40.7 | 36.6 | 42.9 |
| Family history of colorectal cancer (%) | 9.5 | 8.9 | 8.1 | 8.1 | 5.7 | 8.2 | 7.2 | 8.5 |
| Family history of gastric cancer (%) | 6.7 | 5.7 | 5.9 | 5.7 | 7.1 | 6.8 | 5.4 | 5.3 |
| Night shift work history (%) | 16.7 | 17.1 | 16.4 | 15.6 | 20.7 | 16.2 | 16.6 | 17.8 |
| Retired (%) | 50.0 | 45.5 | 38.4 | 52.8 | 65.2 | 41.1 | 36.2 | 60.5 |

Table 3. Effects of daytime napping and sleep duration on colorectal and gastric cancer risk estimates. *Computation of OR in models adjusted for BMI, age, sex, and smoking status. ORs are adjusted for BMI, age, sex, and smoking status in models. (CRC: colorectal cancer, gastric: gastric cancer, N: number of participants, OR: odds ratio, OR°CRC≥9 hours: 2.21, 1.55–3.16)
compared to 7 h of sleep, in both strata. Regular long naps (6–7 days/week, ≥ 30 min) were associated with a greater increase in the odds of colorectal and gastric cancer among participants with night shift work history (CRC: OR6-7 days/week, ≥30 min 1.75, 95%CI 1.23, 2.51; gastric: OR6-7 days/week, ≥30 min 2.54, 95%CI 1.06–6.06), while a weaker or no association was described among participants with no shift work history (CRC: OR6-7 days/week, ≥ 30 min 1.33, 95%CI 1.11–1.61; gastric: OR6-7 days/week ≤ ≥ 30 min 1.19; 0.87–1.63), although the statistical interaction between daytime naps and night work history was not significant.

In stratified analyses by sex, the association between sleep duration and cancer varied slightly across sexes (opposite direction for short and long sleep), but there was no evidence for a statistically significant sex-interaction with sleep duration (Supplemental Table 3). Women in the top category of napping frequency and duration had a higher odds for gastric cancer than men (LRT p-for-interaction = 0.03). In analyses stratified by education associations of sleep duration and cancer were observed across both strata of education (primary or less/high school or more) (Supplemental Table 4). A finer analysis using 4 strata revealed a similar risk pattern for sleep duration (data not shown); results for 9+ hours of sleep were insignificant and weaker among those with the lowest education (less than primary) compared to the rest of the groups. Daytime napping results were stronger in the stratum with lowest education for CRC but results for gastric cancer were similar across strata of education. In stratified analysis by age at diagnosis/interview, the effects of longer sleep duration and daytime napping on colorectal and gastric cancer were more pronounced among participants younger than 50 years than among those older than 50 years, but no statistically significant interaction was observed (Supplemental Table 5). Results for colorectal cancer showed no significant heterogeneity by TNM staging or anatomical site (Supplemental

Figure 1. Multivariable adjusted General Additive Model (GAM) splines for the association (smooth function) of sleep duration and colorectal (A) and gastric (B) cancer risk in the MCC-Spain study. (A) Sleep duration and colorectal cancer (p-Gain = 0.0001). (B) Sleep duration and gastric cancer (p-Gain = 0.0001). Adjusted for age (continuous), centre (Barcelona, Madrid, Leon, Navarra, Cantabria, Guipuzcoa, Valencia, Huelva, Asturias, Granada, Murcia), sex (female, male), and educational level (less than primary, primary, high school, university), family history of colorectal or gastric cancer in first degree relatives (yes/no), body mass index (< 22.5, 22.5–24.9, 25–29.9, ≥ 30), leisure time physical activity (inactive, little active, moderately active, very active), smoking status (never, ex-smoker, current smoker).
Table 3. Sleep duration and daytime napping in relation to colorectal and gastric cancer odds in the MCC-Spain study. aOR adjusted for age (continuous), centre (Barcelona, Madrid, Leon, Navarre, Cantabria, Guipuzcoa, Valencia, Huelva, Asturias, Granada, Murcia), sex (female, male), and educational level (less than primary, primary, high school, university). bOR additionally adjusted for family history of colorectal or gastric cancer in first degree relatives (yes/no), body mass index (<22.5, 22.5–24.9, 25–29.9, ≥30), leisure time physical activity (inactive, little active, moderately active, very active), smoking status (never, ex-smoker, current smoker) and current occupational status (employed, unemployed, housewife, retired).

Table 6). Associations with long sleep duration and napping were a bit stronger for stage IV colorectal cancer but also strong and significant for stage 0–II colorectal tumors. Most of the associations were retained in analyses by anatomical cancer site and Lauren's classification categories for gastric cancer (Supplemental Table 7). Long sleep duration was associated with an increased odds for both tumors located in the colon and rectum, while also strong and significant for stage 0–II colorectal tumors. Most of the associations were retained in analyses excluding participants with report of sleep problems in the 5 years prior to recruitment, results were unchanged (Supplemental Table 8). After the exclusion of retired participants and participants with more than 6 months between the date of diagnosis and interview most results were unchanged or became stronger (data not shown).

Discussion
In this large case–control study we found that participants with longer sleep duration (8 hours and ≥9 hours) had significantly increased odds of colorectal and gastric cancer, compared to those with 7 hours of sleep. Short sleep duration (≤5 hours) was also associated with increased, but not statistically significant, gastric cancer odds. Frequent (6–7 days/week) long (>60 min) naps were associated with increased odds of colorectal and gastric cancer. The effects of short sleep duration and napping were stronger among participants with night shift work history for both tumors.

Long sleep duration was independently associated with colorectal and gastric cancer in our study. Long sleep duration has been associated with higher all-cause and cancer-specific mortality in several meta-analyses including a large number of observational studies. To date, only a few studies have examined the association of sleep duration with cancer risk for tumors other than breast cancer. Our findings for an association of long sleep with CRC are in line with results from two prospective US cohorts of health professionals previously reported an increased risk of CRC among participants with sleep duration of 8 hours and ≥9 hours (compared to 7 hours of sleep), especially among individuals who were overweight or snored regularly. Although we lacked
information on snoring or sleep disordered breathing, our results did not change after adjusting for BMI/obesity and impaired sleep quality, two surrogates of sleep apnoea. Long sleep exhibited a stronger effect on CRC among individuals with a normal BMI. This may indicate that mechanisms other than increased adiposity—a well-known risk factor for CRC and gastric cancer—might be involved in the potential link between long sleep and cancer. A 40% increase in risk of CRC was associated with sleep durations of 10+ hours/day in a cohort of

Table 4. Sleep duration and daytime napping in relation to colorectal and gastric cancer odds in the MCC-Spain study by BMI categories. *p-for interaction (sleep duration) = 0.25, p-for-interaction (daytime napping) = 0.28. **p-for interaction(sleep duration) = 0.002, p-for-interaction(daytime napping) = 0.70. *OR adjusted for age (continuous), sex, centre (Barcelona, Madrid, Leon, Navarra, Cantabria, Guipuzcoa, Valencia, Huelva, Asturias, Granada, Murcia), sex (female, male), educational level (less than primary, primary, high school, university), family history of colorectal cancer or gastric cancer in first degree relatives (yes/no), body mass index (continuous), leisure time physical activity (inactive, little active, moderately active, very active), smoking status (never, ex-smoker, current smoker) and current occupational status (employed, unemployed, housewife, retired).
female lifestyle and obesity. Furthermore, long sleepers were found more likely to be divorced, living alone, working and long sleep duration on total cancer incidence and mortality, breast cancer and lung cancer. Night joint effects on gastrointestinal cancer risk. Although in our study, sleep problems could not be attributed to night sleep, compared to night workers without sleep complaints. Our finding of joint effects between circadian and sleep in future studies of cancer and other chronic disease outcomes.

Sleep disruption is one of the suggested mechanisms for the link between short sleep duration and cancer risk. While in our previous analyses long-term night shift work has been shown to increase the odds of gastric and colorectal cancer,20,21, the present study suggests that short sleep duration and napping may interact with shift work with joint effects on gastrointestinal cancer risk. Although in our study, sleep problems could not be attributed to night shift work, our findings corroborate with a few other studies suggesting combined effects of long-term night shift work and long sleep duration on total cancer incidence and mortality, breast cancer and lung cancer. Night shift work leads to acute sleep loss and impaired sleep quality,31,32, compensational daytime napping on work days and longer sleep on days off,32,33. Shift work related sleep disturbances may become chronic and persist even after quitting shift work,34, and in retirement.35 Shift workers who are especially vulnerable to shift work schedules are more likely to develop “shift work sleep disorder” (SWD) which consists of chronic insomnia and/or daytime sleepiness. However, it is currently unknown if shift workers with SWD are at a greater risk of developing later chronic diseases compared to shift workers without SWD.35 Our results suggest that participants with short sleep and daytime naps may be more susceptible to the negative effects of night work. Alternatively, participants with short shift work history that develop sleep problems might be at a higher risk of colorectal and gastric cancer, compared to night workers without sleep complaints. Our finding of joint effects between circadian and sleep disruption is novel and needs to be confirmed in prospective cohort studies.

Animal and human studies suggest a genetic basis for sleep duration, thus, short and long sleepers may represent phenotypes of the function of clock genes in human sleep.36,40 Experimental data provide a physiological basis for the inter-individual variability and the intra-individual stability of habitual sleep duration.36 Sleep is well known for its contribution to the maintenance of the immune system and regulation of human metabolism.36,41 Several mechanisms for the negative effects of long sleep on mortality have been suggested and discussed by Grandner and Drummond and many of them may have implications for cancer outcomes: First, reported long sleep might reflect disturbances in sleep continuity or sleep architecture and thus may result from impaired sleep quality or fragmented sleep. Second, long sleep has been associated with feelings of fatigue and lethargy which in turn may decrease resistance to stress and disease. Third, long sleep may influence the immune system and expression of cytokines.44–46. Fourth long sleep may be associated with shorter photoperiod and inadequate light exposure patterns.50. Fifth, long sleep has been consistently associated with a more sedentary behaviour, less healthy lifestyle and obesity.50-52. Furthermore, long sleepers were found more likely to be divorced, living alone, unemployed, and have a lower socioeconomic status.60. Sixth, depression or other underlying chronic disease such as sleep apnoea or diabetes that lead to longer sleep or longer time in bed may mediate the association between long sleep and cancer. Last, there is a possibility that poor health including cancer leads to long sleep rather than the opposite.41. On the other hand, several biological mechanisms may explain the potential link between short sleep with cancer risk. Sleep deprivation has been associated with impaired immune function, elevated levels of inflammatory markers and deregulation of cortisol levels that may affect the tumor surveillance system.43,45. Specifically for gastric cancer, a disrupted immune—inflammation balance might promote H. pylori related gastric carcinogenesis.47. Sleep deficiency has been also linked to higher adiposity, metabolic syndrome and type II diabetes that may in turn further increase the risk of cancer.48-50. Furthermore, short sleep duration might be related to increased light-at-night exposure and thus lower nocturnal melatonin levels, a hormone with well-known direct and indirect oncostatic properties.59,60. Finally, sleep loss and/or circadian misalignment may be associated with gut microbiota disruption and subsequent increased risk for metabolic disease and CRC.61,62.

Our study has several limitations. First, reverse causality could partly explain some of the observed associations since cancer status may affect sleep duration and napping habits in both directions (towards more but also less sleep). Similar to most previous epidemiological studies, we assessed current sleep duration and assumed it to be representative of habitual and past sleep duration during adulthood within individuals, but likely reflects relatively recent exposures. In order to address this question, in a follow up of the MCC-Spain study additional
Sleep information was collected at age 40 years and in the year prior to recruitment/cancer diagnosis among breast and prostate cancer cases and respective controls. In preliminary analysis, we found a significant correlation between sleep durations at age 40 and in the year before diagnosis and results did not vary by case–control status (data not shown). These results are supportive of our assumption that current sleep duration assessed in late adulthood could be indicative of past sleep duration in mid adulthood. Furthermore, in our study only incident cases were recruited and interviews were scheduled soon after cancer diagnoses. Our results did not change when we excluded interviews that took place 6 months or later after cancer diagnoses (data not shown).

In order to reduce the potential for reverse causality, we conducted sensitivity analyses excluding participants with sleep problems in the 5 years before diagnosis/recruitment, which did not materially change the results.

In addition, we found no evidence for significant risk variation across colorectal cancer stages in TNM stage-stratified analyses. Second, self-reported sleep duration estimates may contain error and are in poor or moderate

### Table 5

Sleep duration and daytime napping in relation to colorectal and gastric cancer odds in the MCC-Spain study by night shift work history. *p-for interaction (sleep duration) = 0.21, p-for-interaction(daytime napping) = 0.77, *p-for interaction(sleep duration) = 0.30, p-for-interaction(daytime napping) = 0.38. *OR adjusted for age (continuous), sex (male, female), centre (Barcelona, Madrid, Leon, Navarra, Cantabria, Guipuzcoa, Valencia, Huelva, Asturias, Granada, Murcia),, educational level (less than primary, primary, high school, university), family history of colorectal cancer or gastric cancer in first degree relatives (yes/no), body mass index (< 22.5, 22.5–24.9, 25–29.9, ≥ 30), leisure time physical activity (inactive, little active, moderately active, very active), smoking status (never, ex-smoker, current smoker) and current occupational status (employed, unemployed, housewife, retired).

| Night shift work history | Colorectal cancer | Gastric cancer |
|-------------------------|------------------|---------------|
| **Sleep duration (hours)** | Controls (N = 2557) | Cases (N = 1262) | Controls (N = 2180) | Cases (N = 305) |
| Never night shift work | | | | |
| ≤ 5 | 326 | 12.8 | 153 | 12.1 | 0.98 (0.76, 1.25) | 292 | 13.4 | 41 | 13.4 | 1.11 (0.73, 1.71) |
| 6 | 518 | 20.3 | 211 | 16.7 | 0.95 (0.76, 1.18) | 442 | 20.3 | 47 | 15.4 | 0.85 (0.57, 1.28) |
| 7 | 796 | 31.1 | 318 | 25.2 | 1.00 (Ref) | 660 | 30.3 | 74 | 24.3 | 1.00 (Ref) |
| 8 | 701 | 27.4 | 387 | 30.7 | 1.27 (1.05, 1.54) | 602 | 27.6 | 95 | 31.2 | 1.43 (1.02, 2.01) |
| ≥ 9 | 216 | 8.5 | 193 | 15.3 | 1.76 (1.37, 2.27) | 184 | 8.4 | 48 | 15.7 | 2.22 (1.44, 3.43) |

| Daytime napping frequency and duration combined | Controls (N = 605) | Cases (N = 339) | Controls (N = 503) | Cases (N = 88) |
|------------------------------------------------|------------------|---------------|------------------|---------------|
| No naps | 1072 | 43.3 | 454 | 37.0 | 1.00 (Ref) | 910 | 42.6 | 124 | 41.6 | 1.00 (Ref) |
| 1–5 naps/week, < 30 min | 150 | 6.1 | 60 | 4.9 | 0.94 (0.67, 1.31) | 116 | 5.4 | 9 | 3.0 | 0.64 (0.31, 1.32) |
| 6–7 naps/week, < 30 min | 371 | 15.0 | 174 | 14.2 | 0.96 (0.77, 1.20) | 327 | 15.3 | 39 | 13.1 | 0.86 (0.57, 1.32) |
| 1–5 naps/week, ≥ 30 min | 273 | 11.0 | 127 | 10.4 | 1.14 (0.88, 1.47) | 218 | 10.2 | 31 | 10.4 | 1.00 (0.64,1.57) |
| 6–7 naps/week, ≥ 30 min | 610 | 24.6 | 411 | 33.5 | 1.33 (1.11, 1.61) | 564 | 26.4 | 95 | 31.9 | 1.19 (0.87, 1.63) |

| Ever night shift work | Controls (N = 605) | Cases (N = 339) |
|-------------------------|------------------|---------------|
| Sleep duration (hours) | | |
| ≤ 5 | 79 | 13.1 | 52 | 15.3 | 1.69 (1.04, 2.74) | 65 | 12.9 | 18 | 20.5 | 2.75 (1.15, 6.59) |
| 6 | 124 | 20.5 | 58 | 17.1 | 1.16 (0.73, 1.83) | 102 | 20.3 | 13 | 14.8 | 1.40 (0.60, 3.43) |
| 7 | 172 | 28.4 | 68 | 20.1 | 1.00 (ref) | 140 | 27.8 | 12 | 13.6 | 1.00 (Ref) |
| 8 | 154 | 25.5 | 102 | 30.1 | 1.60 (1.06, 2.41) | 128 | 25.5 | 26 | 29.6 | 2.27 (1.01, 5.11) |
| ≥ 9 | 76 | 12.6 | 59 | 17.4 | 1.54 (0.95, 2.51) | 68 | 13.5 | 19 | 21.6 | 2.53 (1.06, 6.06) |

| Daytime napping frequency and duration combined | Controls (N = 503) | Cases (N = 88) |
|------------------------------------------------|------------------|---------------|
| No naps | 249 | 42.2 | 106 | 31.6 | 1.00 (Ref) | 216 | 43.6 | 26 | 30.2 | 1.00 (Ref) |
| 1–5 naps/week, < 30 min | 32 | 5.4 | 15 | 4.5 | 1.40 (0.68, 2.85) | 25 | 5.0 | 4 | 4.7 | 1.52 (0.43, 5.36) |
| 6–7 naps/week, < 30 min | 80 | 13.6 | 48 | 14.3 | 1.27 (0.80, 2.02) | 75 | 15.2 | 10 | 11.6 | 1.31 (0.54, 3.16) |
| 1–5 naps/week, ≥ 30 min | 60 | 10.2 | 27 | 8.0 | 1.21 (0.70, 2.10) | 43 | 8.7 | 9 | 10.5 | 3.25 (1.22, 8.68) |
| 6–7 naps/week, ≥ 30 min | 169 | 28.6 | 140 | 41.7 | 1.75 (1.23, 2.51) | 136 | 27.5 | 37 | 43.0 | 2.97 (1.54, 5.72) |
agreement with objective (polysomnography or actigraphy) measurements in some but not all studies\textsuperscript{33-35}. Participants might have provided information on how many hours they spend in bed instead of actual sleep time, although these two metrics tend to correlate. However, report of current sleep duration is unlikely differential between cases and controls since no recall of past exposure was involved and sleep duration is not a well-known risk factor for cancer, thus, exposure misclassification may have biased our estimates to the null. Third, sleep duration was missing in 8.8\% of CRC controls, 9\% in gastric cancer controls, 6.1\% of CRC cases and 1.5\% in gastric cancer cases, but no differences were found in age, BMI, family history of cancer between participants with and without sleep duration information. Missingness in sleep duration was associated with education and lifestyle (opposite pattern for cases and for controls) but in stratified analyses by education most results were robust. Fourth, we assessed habitual sleep duration once and did not record changes or sustained effects of sleep duration over time, although we controlled for frequent changes of sleeping time that could account for night-to-night variability in sleep duration. Epidemiology is still limited due to constraints in measuring sleep with existing questionnaires\textsuperscript{46}, and future studies should include detailed sleep assessment over critical periods in life that would help reconstruct and evaluate a person’s “lifetime sleep history”\textsuperscript{97}. Fifth, although our study was large, power was limited in stratified analyses, especially for gastric cancer. Sixth, although our study extensively controlled for potential confounders, residual confounding cannot be entirely ruled out. In addition, psychiatric conditions such as depression or anxiety were not assessed and thus not controlled for analytically. Last, similar to other population-based case–control studies low to moderate response rates were observed in both cases and controls, especially among gastric cancer patients due to poor disease prognosis. It is possible that gastric cancer patients with more advanced disease at diagnosis were underrepresented in our study. The reasons for the relatively low response rates may have differed between cases and controls and could have led to selection bias. Participants with a higher socioeconomic or educational status were more likely to participate in the study, especially among controls. However, we found no clear differences of the effects according to groups of education, where selection bias potential would be minimized.

Strengths of this study include the large sample size with enough participants in the categories of extreme sleep duration (29\% reported ≤ 5 h and 10\% reported ≥ 9 h), the collection of information on a wide range of known and suspected risk factors for both tumors and extensive control for potential confounders, including other sleep characteristics such as sleep quality and sleep timing, to account for potential confounding due to impaired sleep. Most results were strong and consistent between colorectal and gastric cancer and remained significant after additional adjustments and in several stratified and sensitivity analyses, suggesting that our findings were unlikely entirely due to chance.

In this large population-based case–control study we described an association of long sleep duration (8 hours and ≥ 9 hours) with increased odds of colorectal and gastric cancer. Short sleep duration (≤ 5 hours) was associated with increased—but not statistically significant—odds of gastric cancer. Short sleep and daytime napping, especially frequent (6–7 days/week) long (≥ 30 min) naps, were associated with increased colorectal and gastric cancer odds, in particular among participants with night shift work history. Our findings support a potential role of extreme nighttime sleep duration and daytime napping in the odds of colorectal and gastric cancer and suggest possible joint effects of sleep and circadian disruption on the risk of gastrointestinal cancer.

Received: 11 February 2021; Accepted: 20 May 2021
Published online: 03 June 2021

References
1. Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394–424. https://doi.org/10.3322/caac.21492 (2018).
2. Dekker, E., Tanis, P. J., Vleugels, J. L. A., Kasi, P. M. & Wallace, M. B. Colorectal cancer. Lancet 394, 1467–1480. https://doi.org/10.1016/S0140-6736(19)32319-0 (2019).
3. Siegel, R. L. et al. Colorectal cancer incidence patterns in the United States, 1974–2013. J. Natl. Cancer Inst. 109. https://doi.org/10.1093/jnci/djw322 (2017).
4. Stone, C. R. et al. The association between sleep duration and cancer-specific mortality: A systematic review and meta-analysis. Cancer Causes Control 30, 501–525. https://doi.org/10.1007/s10552-019-01156-4 (2019).
5. da Silva, A. A. et al. Sleep duration and mortality in the elderly: A systematic review with meta-analysis. BMJ Open 6, e008119. https://doi.org/10.1136/bmjopen-2015-008119 (2016).
6. Kecklund, G. & Axelson, J. Health consequences of shift work and insufficient sleep. BMJ 355, i5210. https://doi.org/10.1136/bmj.i5210 (2016).
7. Cappuccio, F. P., Cooper, D., D'Elia, L., Strazzullo, P. & Miller, M. A. Sleep duration predicts cardiovascular outcomes: A systematic review and meta-analysis of prospective studies. Eur. Heart J. 32, 1484–1492. https://doi.org/10.1093/eurheartj/ehr007 (2011).
8. Shan, Z. et al. Sleep duration and risk of type 2 diabetes: A meta-analysis of prospective studies. Diabetes Care 38, 529–537. https://doi.org/10.2337/dc14-2073 (2015).
9. Cappuccio, F. P. & Miller, M. A. Sleep and cardiometabolic disease. Curr. Cardiol. Rep. 19, 110. https://doi.org/10.1007/s11886-017-0916-0 (2017).
10. Ogilvie, R. P. & Patel, S. R. The epidemiology of sleep and obesity. Sleep Health 3, 383–388. https://doi.org/10.1016/j.sleh.2017.07.013 (2017).
11. Chen, Y. et al. Sleep duration and the risk of cancer: A systematic review and meta-analysis including dose-response relationship. BMC Cancer 18, 1149. https://doi.org/10.1186/s12885-018-5025-y (2018).
12. Zhao, H. et al. Sleep duration and cancer risk: A systematic review and meta-analysis of prospective studies. Asian Pac. J. Cancer Pre vent. 14, 7509–7515. https://doi.org/10.7314/appcp.2013.14.12.7509 (2013).
13. Erren, T. C. et al. Sleep and cancer: Synthesis of experimental data and meta-analyses of cancer incidence among some 1,500,000 study individuals in 13 countries. Chronobiol. Int. 33, 325–350. https://doi.org/10.3109/07420528.2016.1149486 (2016).
14. Wong, A. T. Y. et al. Sleep duration and breast cancer incidence: Results from the Million Women Study and meta-analysis of published prospective studies. Sleep https://doi.org/10.1093/sleep/zsa1166 (2020).
23. Cappuccio, F. P., D’Elia, L., Strazzullo, P. & Miller, M. A. Sleep duration and all-cause mortality: A systematic review and meta-analysis of prospective studies. Sleep 33, 358–592. https://doi.org/10.1093/sleep/33.5.358 (2010).

24. Gallicchio L. & Kalesan, B. Sleep duration and mortality: A systematic review and meta-analysis. J. Sleep Res. 18, 148–158. https://doi.org/10.1111/j.1365-2869.2008.00732.x (2009).

25. Hurley, S., Goldberg, D., Bernstein, L. & Reynolds, P. Sleep duration and cancer risk in women. Cancer Causes Control 26, 1037–1045. https://doi.org/10.1007/s10552-015-0579-3 (2015).

26. Titova, O. E. et al. Sleep duration and risk of overall and 22 site-specific cancers: A Mendelian randomization study. Int. J. Cancer https://doi.org/10.1002/ijc.33286 (2020).

27. Bai, Y. et al. Association of shift–work, daytime napping, and nighttime sleep with cancer incidence and cancer-caused mortality in Dongfeng-tongji cohort study. Ann. Med. 48, 641–651. https://doi.org/10.1080/07853890.2016.1217037 (2016).

28. IARC. Night shift work. IARC Monogr. Identif. Carcinog. Hum. 124A, 1–371 (2020).

29. Wang, P. et al. Night-shift work, sleep duration, daytime napping, and breast cancer risk. Sleep Med. 16, 462–468. https://doi.org/10.1016/j.sleep.2014.11.017 (2015).

30. McNeil, J., Heer, E., Willemsen, R. F., Friedenreich, C. M. & Brenner, D. R. The effects of shift work and sleep duration on cancer incidence in Alberta’s Tomorrow Project cohort. Cancer Epidemiol. 67, 101729. https://doi.org/10.1016/j.canep.2020.101729 (2020).

31. Pilcher, J. J., Lambert, B. J. & Huffcutt, A. I. Differential effects of permanent and rotating shifts on self-report sleep length: A meta-analytic review. Sleep 23, 155–163 (2000).

32. Linton, S. J. How to schedule night shift work in order to reduce health and safety risks. Scand. J. Work Environ. Health https://doi.org/10.1590/s0300-57120140000100010 (2014).

33. Folkard, S. Is there a ‘best compromise’ shift system? Ergonomics 35, 1453–1463; discussion 1465–1465. https://doi.org/10.1080/00140139208967414 (1992).

34. Aeschbach, D. et al. A longer biological night in long sleepers than in short sleepers. J. Clin. Endocrinol. Metab. 88, 26–30. https://doi.org/10.1210/jc.2002-020827 (2003).

35. Sekijima, S. et al. Associations of self-reported sleep duration and snoring with colorectal cancer risk in men and women. Sleep Res. 15, 276–290. https://doi.org/10.1093/sleep/15.3.276 (1992).

36. Wright, K. P. Jr., Bogan, R. K. & Wyatt, J. K. Shift work and the assessment and management of shift work disorder (SWD). Sleep Med. Rev. 17, 41–54. https://doi.org/10.1016/j.smrv.2012.02.002 (2013).

37. Garde, A. H. et al. How to schedule night shift work in order to reduce health and safety risks. Scand. J. Work Environ. Health https://doi.org/10.1590/s0300-57120140000100010 (2014).

38. Grandner, M. A. & Drummond, S. P. Who are the long sleepers? Towards an understanding of the mortality relationship. Sleep Med. Rev. 11, 341–360. https://doi.org/10.1016/j.smrv.2007.03.010 (2007).

39. Youngstedt, S. D. & Kripke, D. F. Long sleep and mortality: Rationale for sleep restriction. Sleep Med. Rev. 8, 159–174. https://doi.org/10.1016/s1299-1810.2003.10002 (2004).

40. Dantzer, R. Cytokine-induced sickness behavior: Mechanisms and implications. Ann. N. Y. Acad. Sci. 933, 222–234. https://doi.org/10.1111/j.1749-6632.2001.tb05827.x (2001).

41. Irwin, M. R. Sleep and inflammation: Partners in sickness and in health. Nat. Rev. Immunol. 19, 702–715. https://doi.org/10.1038/nri.2019.109 (2019).

42. Reynolds, A. M. M., Bowles, E. R., Saxena, A., Fayad, R. & Youngstedt, S. D. Negative effects of time in bed extension: A pilot study. J. Sleep Med. Disord. 1 (2014).

43. Grandner, M. A., Schopfer, E. A., Sands-Lincoln, M., Jackson, N. & Malhotra, A. Relationship between sleep duration and body mass index depends on age. Obesity (Silver Spring) 23, 2491–2498. https://doi.org/10.1002/oby.21247 (2015).

44. Patel, S. R., Malhotra, A., Gottlieb, D. J., White, D. P. & Hu, F. B. Correlates of long sleep duration. Sleep 29, 881–889. https://doi.org/10.1093/sleep/29.7.881 (2006).

45. Stranges, S. et al. Correlates of short and long sleep duration: A cross-cultural comparison between the United Kingdom and the United States: The Whitehall II Study and the Western New York Health Study. Am. J. Epidemiol. 168, 1353–1364. https://doi.org/10.1093/aje/kwn337 (2008).

46. Kronholm, E., Harma, M., Hublin, C., Aro, A. R. & Partonen, T. Self-reported sleep duration in Finnish general population. J. Sleep Res. 15, 276–290. https://doi.org/10.1111/j.1365-2699.2006.00543.x (2006).

47. Ferri, J. E. et al. Associations between change in sleep duration and inflammation: Findings on C-reactive protein and interleukin 6 in the Whitehall II Study. Am. J. Epidemiol. 178, 956–961. https://doi.org/10.1093/aje/kw727 (2013).

48. Haspel, J. A. et al. Perfect timing: circadian rhythms, sleep, and immunity - An NIH workshop summary. JCI Insight 5. https://doi.org/10.1172/jci.insight.131487 (2020).
55. Foss, F. M. Immunologic mechanisms of antitumor activity. *Semin. Oncol.* **29**, 5–11. https://doi.org/10.1053/sonc.2002.33076 (2002).

56. Knutson, K. L. Sociodemographic and cultural determinants of sleep deficiency: Implications for cardiometabolic disease risk. *Soc. Sci. Med.* **198**(2), 7–15. https://doi.org/10.1016/j.socscimed.2015.06.002 (2013).

57. McHill, A. W. & Wright, K. P. Jr. Role of sleep and circadian disruption on energy expenditure and in metabolic predisposition to human obesity and metabolic disease. *Obes. Rev.* **18**(Suppl 1), 13–24. https://doi.org/10.1111/obr.12503 (2017).

58. Padró, S. R. et al. The association between sleep duration and obesity in older adults. *Int. J. Obs. 2005*(32), 1825–1834. https://doi.org/10.1038/issn.2008.198 (2008).

59. Blask, D. E. Melatonin, sleep disturbance and cancer risk. *Sleep Med. Rev.* **13**, 257–264. https://doi.org/10.1016/j.smrv.2008.07.003 (2009).

60. Reiter, R. J. et al. Melatonin, a full service anti-cancer agent: Inhibition of initiation, progression and metastasis. *Int. J. Mol. Sci.* 18. https://doi.org/10.3390/ijms18040843 (2017).

61. Reynolds, A. C. et al. The shift work and health research agenda: Considering changes in gut microbiota as a pathway linking shift work, sleep loss and circadian misalignment, and metabolic disease. *Sleep Med. Rev. 34*, 3–9. https://doi.org/10.1016/j.smrv.2016.06.009 (2017).

62. Wong, S. H. & Yu, J. Gut microbiota in colorectal cancer: Mechanisms of action and clinical applications. *Nat. Rev. Gastroenterol. Hepatol.* **16**, 690–704. https://doi.org/10.1038/s41575-019-0209-8 (2019).

63. Lauderdale, D. S., Knutson, K. L., Yan, I. L., Liu, K. & Rathouz, P. J. Self-reported and measured sleep duration: How similar are they?. *Epidemiology* **19**, 838–845. https://doi.org/10.1097/EDN.0b013e318181a7b0 (2008).

64. Girschik, J., Fritschi, L., Heyworth, J. & Waters, F. Validation of self-reported sleep against actigraphy. *J. Epidemiol.** 22**, 462–468. https://doi.org/10.2188/jea.20120012 (2012).

65. Lockley, S. W., Skene, D. J. & Arendt, J. Comparison between subjective and actigraphic measurement of sleep and sleep rhythms. *J. Sleep Res. 8*, 175–183. https://doi.org/10.1046/j.1365-2869.1999.00155.x (1999).

66. Girschik, J., Heyworth, J. & Fritschi, L. Reliability of a sleep quality questionnaire for use in epidemiologic studies. *J. Epidemiol.** 22**, 244–250. https://doi.org/10.2188/jea.20110107 (2012).

67. Erren, T. C. Sleep duration and cancer risk: Time to use a "sleep-years" index?. *Cancer Causes Control** 23**, 1399–1403. https://doi.org/10.1007/s10552-012-0027-6 (2012).

Acknowledgements

We would like to acknowledge the study participants for their time and energy in completing the interviews and providing us detailed information on their health. We would also like to acknowledge the contribution of all study interviewers, data managers and technicians involved in the data collection.

Author contributions

K.P., G.C.V., M.P., M.K. and V.M. contributed substantially to the conception, study design and acquisition of data. K.P. contributed to the statistical analysis and wrote the first draft of the manuscript. G.C.V., A.E., M.T., M.K. and V.M. contributed substantially to the interpretation of the results and devising the draft of the article. The remaining authors (V.M.S, D.C., N.A, I.G.A, E.A., J.J.J.M., P.A, A.M.B., J.A., G.F.T, J.M.H., N.H.S., B.P.G., J.L., K.P., G.C.V., M.P. and V.M.) contributed substantially to the patients’ recruitment, acquisition of data and critical revision of the manuscript. All authors approved the final version of the manuscript.

Funding

The study was funded by the “Accion Transversal del Cancer”, approved on the Spanish Ministry Council on 11 October 2007, by the Instituto de Salud Carlos III-FEDER (PI08/1770, PI08/0533, PI08/1359, PI09/00773-Cantabria, PI09/01286-León, PI09/01903-Valencia, PI09/02078-Huelva, PI09/01662-Granada, PI11/01403, PI11/01889-FEDER, PI11/00226, PI11/01810, PI11/02213, PI12/00488, PI12/00265, PI12/01270, PI12/00715, PI12/00150), by the Fundación Marqués de Valdecilla (API 10/09), by the ICGC International Cancer Genome Consortium CLL (The ICGC CLL-Genome Project is funded by Spanish Ministerio de Economía y Competitivi-

dad (MINECO) through the Instituto de Salud Carlos III (ISICIII) and Red Temática de Investigación del Cáncer (RTICC) del ISCIII (RD12/0036/0036)), by the Junta de Andalucía (2009-S0143), by the Conselleria de Salud of the Generalitat Valenciana (AP_061/10), by the Consejería de Salud of the Generalitat Valenciana (2010ACUP 00310), by the European Commission grants FOOD-CT-2006-036224-HIWAITE, by the Spanish Association Against Cancer (AECC) Scientific Foundation, by the Catalan Government DURSI grant 2009SGR1489. KP received a predoctoral grant PFIS (FI09/00385). MCT is funded by a Ramón y Cajal fellowship (RYC-2017-01892) from the Spanish Ministry of Science, Innovation and Universities and cofunded by the European Social Fund. ISGlobal acknowledges support from the Spanish Ministry of Science and Innovation through the “Centro de Excelencia Severo Ochoa 2019–2023” Program (CEX2018-000080-S), and support from the Generalitat de Catalunya through the CERCA Program. Agency for Management of University and Research Grants (AGAUR) of the Catalan Government grant 2017SGR723. Spanish Association Against Cancer (AECC) Scientific Foundation. DC is supported by Spanish Ministry of Economy and Competitiveness—Carlos III Institute of Health cofunded by FEDER funds/European Regional Development Fund (ERDF)—a way to build Europe (PI17/01280), the Centro de Investigacion Biomedica en Red: Epidemiología y Salud Publica (CIBERESP, Spain) and the Agencia de Gestio d’Ajuts Universitaris i de Recerca (AGAUR), CERCA Programme/ Generalitat de Catalunya for institutional suport (2017SGR1085). VM is funded by the Agency for Management of University and Research Grants (AGAUR) of the Catalan Government grant 2017SGR723; Instituto de Salud Carlos III, co-funded by FEDER funds—a way to build Europe;—; Spanish Association Against Cancer (AECC) Scientific Foundation. Sample collection of this work was supported by the Xarxa de Bancs de Tumors de Catalunya sponsored by Pla Director d’Oncologia de Catalunya (XBTC)*, Plataforma Biobancos PT13/0010/0013” and ICObioBanc, sponsored by the Catalan Institute of Oncology. We thank CERCA Program, Generalitat de Catalunya for institutional support.
Competing interests
The authors declare no competing interests.

Additional information
Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-021-91275-3.

Correspondence and requests for materials should be addressed to K.P.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021